Skip to Main Content

Moderna Therapeutics finally came through on a long-delayed promise: The well-funded, secretive biotech published data in a peer-reviewed journal. But while the disclosure may satisfy some of the company’s skeptics, a messy legal dispute could imperil Moderna’s ability to make money on its work.

First, the data: In a paper published in Cell on Friday, Moderna’s scientists demonstrated that their mRNA vaccine for Zika virus managed to protect mice against infection. All of the mice on placebo succumbed to the virus after 42 days, while nearly all of the mice who got Moderna’s vaccine survived.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!